May 08, 2019 09:37 JST

Source: Eisai

Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research

TOKYO, May 08, 2019 - (JCN Newswire) - Eisai Co., Ltd. and the UK Dementia Research Institute (UK DRI) announced today the launch of a joint post-doctoral programme to support the advancement of novel dementia research. This first-of-its-kind industry collaboration for the UK DRI aims to deliver innovative research that may translate into improvements in diagnosis, treatment and prevention of all types of dementia.

There are an estimated approximately 50 million dementia patients worldwide. As the ageing of the global population gathers pace, the number of dementia patients worldwide is expected to follow this trend, with the total number of people with dementia projected to reach 82 million in 2030 and 152 million in 2050.(1)

To combat this global issue the UK DRI draws together world-leading expertise into a single national institute that conducts research into all aspects of dementia including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, vascular dementia, and Huntington's disease. Under this joint programme, a grant will be provided to post-doctoral researchers engaged in dementia research from 2019 to 2023.

Researchers will benefit from both the UK DRI's state-of-the-art research facilities and Eisai's drug discovery and translational expertise, and will support the work of the organisation in striving to elucidate novel drug discovery targets and mechanisms, develop novel dementia models, and accelerate the linkage of these research results to diagnostics, treatment and care.

"This collaboration is a wonderful example of UK DRI's desire to work with industry for the greater good of dementia science and patient outcomes. We are grateful for the investment and partnership of Eisai, and indeed for the work of all the dedicated researchers trying to move to new frontiers in conquering dementia. We look forward to seeing more fresh thinking on dementia, and to welcoming our colleagues at Eisai to the UK DRI community of ideas and energy," said Dr. Adrian Ivinson, UK DRI Director and COO.

"Eisai is delighted to be able to initiate this joint programme with the UK DRI, the world's largest dementia research institute." said Dr. Teiji Kimura, Chief Discovery Officer of the Eisai Neurology Business Group. "As the UK DRI's first joint programme with a private company, this programme is a highly unique attempt to provide an environment in which post-doctorate researchers engaged in the world's latest dementia research in the UK will be able to demonstrate the full potential of their capabilities. Under this programme, we hope to realize groundbreaking ideas that can be connected with dementia treatment."

Eisai has been conducting research on neurodegenerative diseases in the UK since 1990. In 2012 the company began a research collaboration with University College London (UCL) which will run until 2023 and was established as part of the company's 'Open Innovation' strategy to collaborate with leading researchers and translate new research findings into innovative treatments for patients with neurodegenerative diseases.

About the UK Dementia Research Institute (UK DRI)

Funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK, the UK DRI draws world-leaders in dementia research into a single national institute. University College London (UCL) is home to the operational headquarters of the UK DRI and forms the hub for research activities across the six national research centres, which are at UCL, the University of Cambridge, Cardiff University, the University of Edinburgh, Imperial College London and King's College London. By convening world-class dementia researchers to bring about ground-breaking approaches to dementia defined by close collaboration and access to exceptional research resources, the UK DRI aims to find better ways to care for patients.

(1) Alzheimer's Disease International. World Alzheimer Report 2018. https://www.alz.co.uk/research/world-report-2018 (Last accessed March 2019).

Contact:
Media Inquiries:

Eisai Co., Ltd.
Public Relations Department 
Tel: +81-(0)3-3817-5120

UK Dementia Research Institute 
Lucy Wilson
Tel: +44 (0)20 3108 6853
Lucy.Wilson@ucl.ac.uk
Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
January 26 2024 15:26 JST
 
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
January 18 2024 14:12 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
January 17 2024 16:08 JST
 
More Press release >>

Latest Press Release


More Latest Release >>